Stoke Therapeutics (NASDAQ:STOK) PT Raised to $22.00 at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK) had its price target boosted by investment analysts at Needham & Company LLC from $14.00 to $22.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price indicates a potential upside of 55.26% from the company’s previous close.

Several other research firms have also issued reports on STOK. Canaccord Genuity Group lifted their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $19.63.

Stoke Therapeutics Stock Up 37.7 %

STOK stock opened at $14.17 on Tuesday. The firm has a market cap of $632.69 million, a price-to-earnings ratio of -5.98 and a beta of 0.68. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $16.40. The company’s fifty day simple moving average is $5.88 and its 200 day simple moving average is $4.95.

Insider Transactions at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at $423,035. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at approximately $423,035. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $5.74, for a total transaction of $57,400.00. Following the completion of the sale, the insider now directly owns 16,981 shares of the company’s stock, valued at $97,470.94. The disclosure for this sale can be found here. Insiders sold a total of 37,615 shares of company stock valued at $212,852 over the last three months. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Stoke Therapeutics by 24.3% in the second quarter. BlackRock Inc. now owns 2,293,670 shares of the company’s stock valued at $24,382,000 after acquiring an additional 448,175 shares during the last quarter. Vanguard Group Inc. boosted its stake in Stoke Therapeutics by 2.7% in the third quarter. Vanguard Group Inc. now owns 2,047,904 shares of the company’s stock valued at $26,295,000 after acquiring an additional 52,871 shares during the last quarter. Lynx1 Capital Management LP purchased a new position in Stoke Therapeutics in the third quarter valued at about $6,738,000. Goldman Sachs Group Inc. boosted its stake in Stoke Therapeutics by 976.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,391,431 shares of the company’s stock valued at $7,319,000 after acquiring an additional 1,262,126 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Stoke Therapeutics in the first quarter valued at about $25,011,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.